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Abstract
Objectives
Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST
response to induction chemotherapy (ICT) in locoregionally advanced head and neck squa-
mous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment
tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were
prognostic for long-term survival outcomes.
Methods
A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cis-
platin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modu-
lated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
before and after two cycles of ICT was used to measure Fp and RECIST response.
Results
Forty-two patients were recruited and 37 underwent two scans. The median follow-up was
36 (range 23–49) months. Pre-treatment tumour Fp (stratified by median) was not prognos-
tic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control
(p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was
prognostic for any outcome (p>0.21).
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Conclusion
DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST
response to ICT may not be an appropriate endpoint to determine early efficacy of a treat-
ment in HNSCC patients.
Introduction
Head and neck cancer is one of the world’s leading malignancies with an estimated global inci-
dence of over 686,000 cases in 2012. In Europe in 2013, head and neck cancer contributed
135,400 new oncology diagnoses and 61,300 deaths.[1] Concurrent chemoradiotherapy is the
non-surgical standard of care for patients who present with high stage disease.[2–4] Despite
advances in chemoradiotherapy, unlike some other cancer sites where survival rates rose substan-
tially in recent decades, the improvement in head and neck cancer survival rates has been modest.
As chemotherapy primarily acts as a radiosensitiser for locoregional treatment in head and neck
squamous cell carcinoma (HNSCC),[5] the use of induction chemotherapy (ICT) has been
explored to tackle distant metastases.[6] The preferred ICT regimen comprises a taxane (T), plati-
num agent (P) and 5-fluorouracil (F) (TPF) [7–10] and has been shown in several studies to lower
distant metastasis rates compared with CRT alone.[5, 7, 11–13] Despite this, there is controversy
as to whether this translates to an improved overall survival outcome.[14, 15] It has been sug-
gested, however, that as well as several problems with poor methodology undermining the appli-
cability of trials comparing ICT to CRT alone; trials have included patients that are unlikely to
benefit from the potential advantages of ICT such as those with a low risk of distant metastases,
hence diluting any positive effects.[14] Tumour heterogeneity also affects response to treatment.
[16] The key to extracting the benefits of ICT may be meticulous patient and tumour selection.
Three cycles of TPF take nine weeks to complete. Approximately 30% of patients do not
respond to ICT and hence may have their definitive treatment delayed for little if any benefit.
[8, 17] Methods to detect prior to or early in the course of ICT which patients are unlikely to
respond would identify patients who should be directed immediately to CRT to prevent delays
in definitive locoregional treatment.
Zima et al [18, 19] showed that HNSCCs with elevated blood volume and blood flow detected
by pre-treatment computed tomography (CT) perfusion imaging had a good response to ICT.
Petralia et al [20] also found baseline tumour blood volume in patients with upper aerodigestive
tract squamous cell carcinomas was significantly lower in non-responders to ICT as demonstrated
by perfusion CT. Our group set up a study to investigate whether similar findings were seen with
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and showed that pre-treat-
ment tumour plasma perfusion (Fp) predicts response to ICT.[17] Whether the prediction of early
response to ICT relates to long-term survival outcomes, however, is not known. This study there-
fore investigated whether the pre-treatment tumour Fp estimate, plus changes in tumour Fp or
RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes.
Materials and methods
Patients
Ethical approval was granted by The North West 1 Research Ethics Committee (ref: 11/
H1017/5) and The Christie Research and Development Department for a prospective open
cohort study to recruit 50 patients. Recruitment started in March 2011 and the 50th patient
was recruited in July 2013. All patients gave written informed consent. Patients were eligible if
they had histologically or cytologically proven stage IV HNSCC (staged according to American
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Joint Committee on Cancer (AJCC) using the tumour, node, metastases (TNM) system [21])
and had been referred for treatment with three cycles of ICT followed by CRT as decided by The
Christie Head and Neck multidisciplinary team. ICT was a modified version of the TAX 323
doses [7] planned as three cycles of: docetaxel (75 mg/m2 IV on day 1), cisplatin (75 mg/m2 IV
on day 1) and 5-FU (750 mg/m2 IV on days 2–5) followed by two weeks of rest. Following the
two-week rest period after the third cycle of TPF, patients were given concurrent CRT involving
intensity-modulated radiation therapy (IMRT) with 66 Gy in 30 fractions plus concurrent cis-
platin (100 mg/m2 IV) at the beginning of week 1 and week 4 (day 1 and 22). It has been sug-
gested that ICT and CRT provide different benefits for advanced HNSCC with CRT mainly
producing locoregional control and ICT controlling distant metastases hence complimenting
each other’s strengths.[5] As part of this study was to understand which patients may or may not
benefit from ICT as an neoadjuvant to the current gold standard CRT treatment and as efforts to
determine a standard CRT regimen post ICT are ongoing separately [6]; we used this well recog-
nised chemoradiotherapy regimen suitable for use as a primary therapy without ICT as per
Pignon 2009.[5] Patients were excluded from the trial if they had undergone any previous treat-
ment for a head and neck carcinoma. P16 status was determined as described elsewhere.[17]
Imaging protocol
Baseline imaging was acquired in the three weeks before ICT. The imaging protocol is
described in detail elsewhere.[17] Briefly, the examination consisted of conventional staging
scans followed by high resolution T2-weighted (w) imaging, a saturation-recovery measure-
ment of T1, and dynamic T1w imaging for a total of 7 minutes during which a bolus injection
of 0.1 mmol/kg Gadobutrol (Gd) was administered in an antecubital vein. DCE-MRI analysis
was on a whole-tumour region of interest basis (outlined on high resolution T2w images by
two radiologists in consensus). The two compartment exchange model [22] was fitted to the
Gd concentration vs time curves, which were converted from signal intensity vs time curves
using a precontrast measurement of T1.[23] Arterial input functions were obtained from the
internal carotid artery on a patient by patient basis using an automated procedure.[24]
A further DCE-MRI examination was acquired during the two-week window between the
second and third cycles of ICT. Fp of the primary tumour and largest regional lymph node was
determined on the second scan. Patients were divided into complete responders, partial
responders and those with stable disease according to the Response Evaluation Criteria in
Solid Tumours (RECIST 1.1).[25]
Study design
The prospective study was designed and powered to detect early response to ICT based on
published data. The power calculation indicated a need for 38 patients to have a pre-treatment
DCE-MRI scan to detect a one standard deviation difference in microvascular parameters
with 77% power. Fifty patients were recruited to the trial and 42 completed the baseline
DCE-MRI scan. Thirty-seven patients completed both the baseline DCE-MRI scan and the fol-
low-up scan after two cycles of ICT. Fig 1 shows a flow diagram indicating the reasons for
exclusion from the trial. The results of the primary analysis of the study have been published.
[17] Secondary endpoints of the study were to assess relationships with long-term outcomes
for: baseline Fp of the primary lesion and / or largest regional lymph node; the change in Fp of
the primary lesion and / or largest regional lymph node between the baseline DCE-MRI scan
and the second DCE-MRI scan (post two cycles of ICT); and RECIST response between the
baseline and second DCE-MRI scan (post two cycles of ICT) using target lesions from both
the primary tumour and nodal metastases as per RECIST guidelines version 1.1. [25]
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Statistical analysis
IBM SPSS Statistics 22 (IBM, Armonk, USA) was used for all statistical analyses. Patients were
stratified by median Fp of the primary tumour and by the largest regional lymph node.
Kaplan-Meier curves were plotted for these groups with respect to overall survival (OS), dis-
ease-specific survival (DSS) and locoregional control (LRC) measured from date of first day of
treatment. Fp values were also determined in patients undergoing the second DCE-MRI scan
(after two cycles of ICT). Pre-treatment values were then subtracted to obtain a value for the
change in Fp. Patients were again stratified by median Fp of the primary tumour and largest
regional lymph node. Patients were also stratified by RECIST response defined as complete or
partial (CR or PR) versus stable or progressive disease (SD or PD). Cox regression was used to
assess differences in outcome between all groups.
Results
Table 1 summarizes the patient characteristics for the group. Median follow-up in surviving
patients was 36 months (range 23–49 months). ICT was stopped and treatment changed to
Fig 1. Flow diagram showing patient inclusion and exclusion from the trial.
https://doi.org/10.1371/journal.pone.0194841.g001
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palliation in one patient following identification of pre-treatment lung metastases. This patient
was included in the OS analyses (on an intention to treat basis) but was excluded from the DSS
and LRC analyses.
Median survival was not calculated because a 50% event rate was not reached for any
group. At a median 3-year follow up OS for the whole group was 74.1%, DSS 87.6% and LRC
87.4%. Median tumour Fp was 43.8 ml/100ml/min, interquartile range 25.5–81.5 ml/100ml/
min. As shown in Table 2, there were no statistically significant differences in OS (p = 0.42),
Table 1. Trial patient and tumour characteristics.
Characteristic Number Percent (%)
Age (years) Median (range) 56 (38–73) -
Gender Male 38 90.5
Female 4 9.5
Primary site Oral cavity 2 4.8
Oropharynx 31 73.8
Nasopharynx 2 4.8
Hypopharynx 7 16.7
Grade Moderately differentiated 20 47.6
Poorly differentiated 17 40.5
Unknown 5 11.9
Tumour classificationa T2 13 31.0
T3 14 33.3
T4 15 35.7
Node classificationa N0 3 7.1
N1 1 2.4
N2 34 81.0
(N2b) (22) 52.4
(N2c) (12) 28.6
N3 4 95.2
Stagea Iva 37 88.1
IVb 5 11.9
IMRT Yes 41 97.6
No 1 2.4
WHO performance status 0 31 73.8
1 10 23.8
2 1 2.4
P16 status (whole group) Positive 30 71.4
Negative 10 23.8
Unknown 2 4.8
P16 status (oropharynx) Positive 27 87.1
Negative 2 12.9
Unknown 2 12.9
Smoking Status Never 9 21.4
Ex </ = 1 year 8 19.0
Ex > 1 year 15 35.7
Current 10 23.8
IMRT: Intensity-modulated radiation therapy; WHO: World Health Organisation; HPV: Human papilloma virus; ISH: In situ hybridization.
aAccording to American Joint Committee on Cancer staging [21].
https://doi.org/10.1371/journal.pone.0194841.t001
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DSS (p = 0.20) or LRC (p = 0.64) for patients with low versus high pre-treatment tumour Fp.
Median nodal Fp was 28.19ml/100ml/min, interquartile range 18.01–55.20 ml/100ml/min.
There were no statistically significant differences in OS (p = 0.88), DSS (p = 0.30) or LRC
(p = 0.92) for patients with low versus high nodal Fp. Fig 2 shows the Kaplan-Meier curves for
tumour and nodal Fp versus OS, DSS and LRC.
Change in primary tumour Fp was available for 37 patients and change in nodal Fp for 32
patients. Using Cox regression analysis, changes in Fp between the pre-treatment DCE-MRI
and the DCE-MRI post two cycles of ICT had no prognostic significance (Table 2).
RECIST response between the pre-treatment MRI and the MRI post two cycles of ICT was
available in 37 patients. One patient had CR, 23 patients had PR, 13 patients had SD and no
patients had PD. The outcomes for patients with a CR or PR versus SD were not statistically
significant for any outcome measures as shown in Table 2. Fig 3 shows Kaplan-Meier curves
for RECIST response versus outcome.
Results from univariable analysis of smoking status, performance status,[26] p16 status,
tumour differentiation and nodal grade with regards to survival outcome are beyond the scope
of this article but can be found in supporting information S1 Table.
Discussion
The primary analysis of the study showed that high pre-treatment tumour Fp evaluated using
pre-treatment DCE-MRI imaging in high stage HNSCC predicts initial response to ICT.[17]
The secondary analysis reported here showed that this early prediction of good response to
ICT did not correlate with good long term outcomes. Also, neither change in plasma perfusion
post two cycles of ICT nor RECIST response were prognostic for long-term survival outcomes.
Table 2. Results from univariable Cox regression analyses.
Outcome measure (frequencya) Overall survival P value Disease specific P value Locoregional control P value
HR (95% CI) survival HR (95% CI) HR (95% CI)
Tumour
<median (21) 1 1 1
median (21) 0.59 (0.17–2.10) 0.42 0.24 (0.03–2.10) 0.20 0.65 (0.11–3.91) 0.64
Nodal Fp
<median (19) 1 1 1
median (20) 1.11 (0.30–4.13) 0.88 0.30 (0.03–2.87) 0.30 0.91 (0.13–6.43) 0.92
Change in
tumour Fp
<median (18) 1 1 1
median (19) 1.05 (0.28–3.91) 0.95 0.01 (0.00–44.91) 0.30 0.25 (0.03–2.21 0.21
Change in
nodal Fp
<median (16) 1 1 1
median (16 0.55(0.13–2.30) 0.41 0.49 (0.04–5.38) 0.56 0.95 (0.13–6.73) 0.95
RECIST response
CR or PR (24) 1 1 1
SD (13) 0.95 (0.24–3.80) 0.94 0.61 (0.06–5.86) 0.66 0.44 (0.05–3.90) 0.44
aOne patient included in the overall survival (OS) group on an intention to treat basis was not included in the DSS and LRC analyses. This patient was excluded from
further analyses as it became apparent during induction chemotherapy that the patient had distant metastases. Induction chemotherapy was abandoned and treatment
was swapped to palliative.
https://doi.org/10.1371/journal.pone.0194841.t002
DCE-MRI perfusion parameters and RECIST response do not predict HNSCC outcomes post ICT
PLOS ONE | https://doi.org/10.1371/journal.pone.0194841 March 28, 2018 6 / 14
DCE-MRI perfusion parameters and RECIST response do not predict HNSCC outcomes post ICT
PLOS ONE | https://doi.org/10.1371/journal.pone.0194841 March 28, 2018 7 / 14
The tumour microenvironment affects the delivery and penetration of chemotherapy to
malignant cells and so impaired tumour perfusion leads to a poor treatment response.[27–29]
It is therefore reasonable to expect that Fp (Fp is equivalent to blood flow [BF] adjusted for hae-
matocrit) might be prognostic for long term outcomes. Indeed, several HNSCC studies show
pre-treatment tumour hypoxia and haemodynamic imaging parameters such as blood volume
(BV) and BF are prognostic for survival outcomes [30–37] although there are conflicting
reports.[38] However, these studies were performed on patients receiving definitive locoregio-
nal treatment such as XRT or CRT rather than ICT. Published trials assessing perfusion
parameters relating to ICT predominantly report initial response to ICT treatment only.[18–
20] Hence, whilst there is evidence that tumour perfusion parameters can predict immediate
Fig 2. Tumour plasma perfusion (Fp) in relation to overall survival (a), disease specific survival (b) and locoregional control (c).
Nodal plasma perfusion in relation to survival (d) disease specific survival (e) and locoregional control (f).
https://doi.org/10.1371/journal.pone.0194841.g002
Fig 3. RECIST response to induction chemotherapy in relation to overall survival (a), disease specific survival (b) and
locoregional control (c).
https://doi.org/10.1371/journal.pone.0194841.g003
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response to ICT, ours is one of the first studies to assess long term outcomes. Despite pre-treat-
ment Fp predicting initial response to ICT,[17] it does not equate to long term survival benefit.
This result was echoed by Bisdas et al who found that baseline BV and BF predicted initial ICT
response. However, it was noted that progression free survival in the responder group was not
significantly different to the non-responders group (p = 0.80).[39] Nevertheless, stratifying
patients to different treatments based on initial ICT response is currently performed in clinical
practice. The RTOG 91–11 study [40] designed a trial modelled on the Department of
Veterans Affairs Laryngeal Cancer Study Group trial of 1991 where patients in the ICT arm
received either a further cycle of ICT then radiotherapy or salvage surgery depending on their
response post 2 cycles of ICT. Urba et al 2006 [41] also suggested that single cycle ICT selects
patients for organ sparing treatment rather than total laryngectomy depending on initial ICT
response. There are differences in what constitutes a good or poor response to treatment rang-
ing from “no response” to “50% response” to a “major response” and varying numbers of pre-
liminary cycles of ICT given. In clinical practice, initial response to ICT is thought to suggest a
tumour’s inherent treatment responsiveness and is considered an aid for subsequent treatment
decisions. Our study suggests, however, that this practice of using response to ICT as a tool to
stratify patients to different locoregional treatments may need to be revisited as an inadequate
response to ICT may not translate into a poor outcome post CRT.[41] Larger trials are needed
to verify our results.
A possible explanation for the lack of prognostic significance might be intra-tumoural het-
erogeneity. Tumours can have sub-regions with variable blood flow, architecture, metabolism,
cell proliferation, genotypes and phenotypes.[42–45] Gerlinger et al reported that “gene
expression signatures of poor and good prognosis were detected in different regions of the
same tumour”.[44] ICT is used predominantly to tackle distant micrometastases as an adjunct
to definitive treatment and although potentially producing considerable tumour and nodal
shrinkage, there is only a complete response in 0–40% of patients.[17, 20] It may be that the
prognostic features of the remaining tissue are what ultimately determine the response to
locoregional treatment and survival outcome. This may explain some of the discrepancies
between findings based on patients treated solely with locoregional treatment of (chemo)
radiotherapy and those treated with ICT first which best tackles distant metastases.
In 1996 the Food and Drug Administration stated that more cancer drugs would be granted
accelerated approval if their benefit could be demonstrated by objective evidence of tumour
shrinkage.[46] It was noted that evidence of better survival could now be demonstrated later
implying that tumour shrinkage and survival benefit were related. There is evidence that in
several cancer sites that this is the case.[47, 48] Studies including a meta-analysis by El-Mara-
ghi and Eisenhauer showed that objective tumour response was a useful endpoint in phase II
trials for several solid tumours as its observation predicted for eventual success in phase III tri-
als.[49, 50] However, HNSCC were not included in these trials and the result was not seen in
all subsites studied.
The relationship between objective tumour shrinkage (RECIST response) and long term
outcomes has not been extensively studied in HNSCC but, like our study, those performed in
HNSCC suggest RECIST response cannot be used a surrogate marker for long term survival
outcomes. Passero et al found no relationship between a complete RECIST response measured
by CT and progression free survival (PFS) in 53 HNSCC patients treated with concurrent CRT
+/- ICT.[51] Matoba et al found no relationship between RECIST response measured using
MR prior to and eight weeks post CRT on locoregional control or survival.[52] Studies have
shown that RECIST response measured by CT does not correlate with pathological response
in HNSCC, which may explain why RECIST response is an unreliable predictor of long-term
outcome.[53, 54] Hence, although a widely used method of measuring change in tumour size
DCE-MRI perfusion parameters and RECIST response do not predict HNSCC outcomes post ICT
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in regular clinical use and as part of the reporting of trial outcomes, RECIST response appears
to have no value as a prognostic factor for long-term survival outcomes in HNSCC. This find-
ing has practical implications as RECIST response is used frequently in clinical practice and
trial reporting despite a lack of evidence supporting its use for HNSCC. There is, therefore, a
need for larger clinical trials investigating initial RECIST response to treatment in relation to
long term survival outcomes, which need to investigate the effect of the treatment regimen
used, i.e. CRT alone or with additional ICT.
Limitations of this study are that it is single-centre and non-randomized. Also, the study
was powered to assess the relationship between pre-treatment DCE-MRI parameters and
RECIST response rather than relationships with long-term outcomes. Strengths are that it is
prospective and focuses on the patient group most likely to benefit from TPF ICT, i.e., those
with stage IV disease (and hence high risk of distant metastases). This cohort, therefore, is a
representative group of patients that is most likely to be offered this treatment regimen.
Regarding future studies, larger trials are required to validate our study results in relation to
using initial ICT response and RECIST response as an aid to treatment stratification. Further
studies into intra-tumour heterogeneity and how it correlates with outcomes following ICT
are also required.
Conclusions
Pre-treatment tumour Fp, change in tumour Fp measured using DCE-MRI and RECIST
response post two cycles of ICT are not prognostic for long-term survival outcome in HNSCC
patients treated with ICT followed by chemotherapy and IMRT. Intra-tumour heterogeneity
post ICT may explain the inability to predict long-term outcomes prior to treatment. RECIST
response to ICT may not be an appropriate endpoint to determine efficacy of treatment in a
clinical or phase II trial setting for HNSCC patients.
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